To investigate the clinical efficacy and safety of trametinib in the second-line treatment of advanced NSCLC with KRAS G12C mutations.
Key Findings:
Objective response rate (ORR) was 27.8% (5/18).
Disease control rate (DCR) was 72.2% (13/18).
Median progression-free survival (PFS) was 3.8 months.
Median overall survival (OS) was 8.6 months.
Higher ORR in patients without bone metastasis (35.7% vs. 0%).
DCR was greater in patients with PD-L1 expression ≥1% (81.8% vs. 50.0%).
Common adverse reactions included rash (35.0%), diarrhea (25.0%), and fatigue (20.0%).
Interpretation:
Trametinib demonstrated anti-tumor activity and manageable toxicity in advanced NSCLC with KRAS G12C mutations, with certain clinical factors potentially influencing treatment response.
Limitations:
Small sample size of 20 patients.
Retrospective design may introduce bias.
Lack of control group.
Conclusion:
Trametinib is evaluated as a second-line treatment for advanced NSCLC with KRAS G12C mutations, pending further validation through larger studies.
